EU Accession Reference Pricing
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
International reference pricing has grown from an evolving cost-containment philosophy in Western Europe, to a trusted policy tool readily adopted by emerging markets around the world. As, Croatia, Macedonia and Turkey are considered more seriously for EU accession, pharmaceutical budgetary controls will be one aspect that enables them to conform to the European ‘single-market’. Policy changes in these countries will arrive quickly as the countries’ accessions become more certain. Pharmaceutical multinationals doing business in these markets must monitor these changes closely, while paying close attention to lessons offered through recent accession markets, like Romania and Bulgaria.
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.